No headlines found.
Globe Newswire (Mon, 17-Nov 7:00 AM ET)
BioRestorative Therapies Reports Third Quarter 2025 Financial Results and Provides Business Update
Globe Newswire (Wed, 12-Nov 4:05 PM ET)
Globe Newswire (Wed, 5-Nov 4:30 PM ET)
Globe Newswire (Mon, 27-Oct 7:30 AM ET)
Globe Newswire (Wed, 22-Oct 9:35 AM ET)
BioRestorative Therapies to Participate in the 2025 Maxim Growth Summit
Globe Newswire (Wed, 15-Oct 9:35 AM ET)
BioRestorative CEO Lance Alstodt Interviewed on "The Big Biz Show"
Globe Newswire (Tue, 7-Oct 9:25 AM ET)
BioRestorative Therapies Announces $1.085 Million Registered Direct Offering Priced Above Market
Globe Newswire (Mon, 6-Oct 2:28 PM ET)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
Biorestorative Therapies trades on the NASDAQ stock market under the symbol BRTX.
As of December 24, 2025, BRTX stock price climbed to $1.19 with 16,786 million shares trading.
BRTX has a beta of 0.63, meaning it tends to be less sensitive to market movements. BRTX has a correlation of 0.03 to the broad based SPY ETF.
BRTX has a market cap of $10.56 million. This is considered a Sub-Micro Cap stock.
Last quarter Biorestorative Therapies reported $11,800 in Revenue and -$.33 earnings per share. This fell short of revenue expectation by $-424,200 and exceeded earnings estimates by $.05.
In the last 3 years, BRTX traded as high as $7.13 and as low as $.98.
The top ETF exchange traded funds that BRTX belongs to (by Net Assets): VXF.
BRTX has underperformed the market in the last year with a return of -21.7%, while the SPY ETF gained +17.3%. In the last 3 month period, BRTX fell short of the market, returning -17.9%, while SPY returned +4.4%. However, in the most recent 2 weeks BRTX has outperformed the stock market by returning +11.2%, while SPY returned +1.4%.
BRTX support price is $1.09 and resistance is $1.23 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BRTX shares will trade within this expected range on the day.